Rebecca Romano
Family · Glenview, ILNPI 1821795162
Payments from drug & device makers
Across 138 payments — averaging $21.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$486
- AstraZeneca$352
- Amneal Pharmaceuticals LLC$346
- Lilly USA, LLC$326
- GSK$256
- Amgen$240
- plus $1K from 15 others
What the payments were for
- Food & beverage$3,006100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 23 | $486 |
| AstraZeneca | 17 | $352 |
| Amneal Pharmaceuticals LLC | 18 | $346 |
| Lilly USA, LLC | 13 | $326 |
| GSK | 11 | $256 |
| Amgen | 13 | $240 |
| Pfizer | 7 | $179 |
| AbbVie | 8 | $169 |
| Coloplast | 1 | $79 |
| Exact Sciences | 4 | $78 |
| Merck | 4 | $73 |
| Esperion Therapeutics, Inc. | 4 | $71 |
| Agios Pharmaceuticals, Inc. | 2 | $58 |
| Boehringer Ingelheim | 2 | $53 |
| Medtronic | 1 | $53 |
| Sanofi Pasteur Inc. | 2 | $48 |
| Abbott | 2 | $39 |
| Noven Therapeutics, LLC | 2 | $35 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Biotronik NRO, Inc. | 1 | $20 |
| Mayne Pharma Commercial LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPBOUND$124
How this compares
$3,006 in reported general payments places this provider in the 85th percentile of 4,941 family providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 12 | $14,718 |
| Ezetimibe | 30 | $1,346 |
| Rosuvastatin Calcium | 99 | $905 |
| Atorvastatin Calcium | 42 | $490 |
| Lorazepam | 20 | $274 |
| Escitalopram Oxalate | 16 | $271 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $270 |
| Levothyroxine Sodium | 20 | $245 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 12 | $245 |
| Alendronate Sodium | 19 | $217 |
| Olmesartan Medoxomil | 15 | $215 |
| Losartan Potassium | 17 | $198 |
| Methylprednisolone | 34 | $194 |
| Amlodipine Besylate | 31 | $193 |
| Lisinopril | 23 | $161 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $326 | $14,71812 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $346 | $24520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,941 family providers in Illinois.
Other family in Glenview
- Brooke PhenicieGlenview$105K
- Ruth CarricoChicago$582K
- Aleksandra BielawiecBarrington$373K
- Erin SieberNaperville$334K
- Jamie BroganChicago$282K
- Ashley NoethGlen Carbon$271K
- Marita KametasChicago$259K
- Shammona ClarkChicago$247K
- Amanda McKeeMount Vernon$242K
- Brooke KennardBloomington$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.